Kids & teens (for parents) · District of Columbia
Studies for children and teens in District of Columbia
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
28 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
Lumos Pharma
- Location
- Washington D.C., DC + 30 other US sites
- Eligibility basics
- Ages 3–11
- RecruitingPhase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer
- Location
- Washington D.C., DC + 18 other US sites
- Eligibility basics
- Ages 6–14
- RecruitingPhase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Pfizer
- Location
- Washington D.C., DC + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Incyte Corporation
- Location
- Washington D.C., DC + 6 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2/Phase 3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Merck Sharp & Dohme LLC
- Location
- Washington D.C., DC + 7 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
AstraZeneca
- Location
- Washington D.C., DC + 18 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Ascendis Pharma A/S
- Location
- Washington D.C., DC + 21 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 1
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Pfizer
- Location
- Washington D.C., DC + 10 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Neuren Pharmaceuticals Limited
- Location
- Washington D.C., DC + 16 other US sites
- Eligibility basics
- Ages 3–12
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Washington D.C., DC + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Washington D.C., DC + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Washington D.C., DC + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active…
AbbVie
- Location
- Washington D.C., DC + 4 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Washington D.C., DC + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
AbbVie
- Location
- Washington D.C., DC + 11 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 2/Phase 3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Merck Sharp & Dohme LLC
- Location
- Washington D.C., DC + 19 other US sites
- Eligibility basics
- Ages 1 mo–17
- RecruitingPhase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc.
- Location
- Washington D.C., DC + 14 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company
- Location
- Washington D.C., DC + 39 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals
- Location
- Washington D.C., DC + 3 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 2
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
BioMarin Pharmaceutical
- Location
- Washington D.C., DC + 30 other US sites
- Eligibility basics
- Ages 3–11
- RecruitingPhase 3
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals
- Location
- Washington D.C., DC + 6 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 2/Phase 3
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Calcilytix Therapeutics, Inc., a BridgeBio company
- Location
- Washington D.C., DC + 3 other US sites
- Eligibility basics
- Ages 0 mo–17
- RecruitingPhase 2
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Merck Sharp & Dohme LLC
- Location
- Washington D.C., DC + 8 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
- Location
- Washington D.C., DC + 1 other US site
- Eligibility basics
- Ages 6–17